In this research report Transparency Market Research analyzes the global high-potency active pharmaceutical ingredients market (HPAPI) along with market dynamics and present market condition. It also covers the market of high-potency active pharmaceutical ingredients types and application in different regions of the world namely, North America, Europe, Asia and RoW along with their sub segments. Moreover, the report provides detailed and in-depth analysis of the HPAPI market, with their estimated figures and forecast from 2012 to 2018, along with compound annual growth rate from 2012 to 2018.
The global high-potency active pharmaceutical ingredients market has shown favorable growth trend in the last few years and is expected to grow rapidly in the forecasted period. The demand of oncology products is further expected to drive the growth of this market. The high level of competition in this market is due to new entrants fragmenting the market. HPAPI market by type of synthesis has been covered in this report providing their estimates and forecast from 2012 to 2018. The drivers, restraints and opportunities have also been covered broadly in this report along with their impact analysis. These market dynamics will be highly helpful in taking corporate decisions related to the HPAPI market.
High potency active pharmaceutical ingredients (HPAPIs) are growing rapidly as compared to other segments of the healthcare industry. HPAPI are the compounds helpful in the treatment of respiratory disorders, treatment of cancer and hormonal imbalances. Growing oncology therapeutics market worldwide is the key factor driving the growth of this market.
High Potency Active Pharmaceutical Ingredients Market is a growing concept and is considered to be a boost to the pharmaceutical industry. Patented high potency drug development majorly dominates the HPAPI market. The branded sector constitutes the major share of this market but the patents of this branded sector are expected to expire in the coming few years that will help HPAPI manufacturers to cater to multiple clients by producing the generic version of the ingredients in bulk.
Some of the factors driving this market at a rapid growth rate are majority of blockbuster drugs nearing patent expiry, US government promoting generic drugs to reduce its medical burden, insurance companies preferring generic drugs over patented drugs for cost effectiveness and India and China with maximum DMFs with the US FDA.
However, a large number of competitors are entering this market making it highly fragmented which may slow down the growth of this market. Moreover, reduced R&D investments leading to low demand of HPAPIs and shortage of US FDA approved manufacturing sites are also likely to be the major restraints for the growth of the high potency active pharmaceutical ingredients market.
However, North America has been the largest market for high potency pharmaceutical ingredients as the country spends highly on the development of healthcare systems, whereas the European market has experienced several fluctuations in the past few years but is expected to grow rapidly in the near future due to rise in the demand of oncology drugs in this region.